GlassScriptPhysician profile
John Daniel Herlihy
NPI 1245625151
$13,113.77
in general payments reported to CMS, 2019-2025
50 companies · $1,504 in 2025
The $1,504 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,650 · 2020: $13.17 · 2021: $757 · 2022: $2,635 · 2023: $2,554 · 2024: $4,001 · 2025: $1,504.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,761 · Travel and Lodging: $1,276 · Education: $22.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,760.76 |
| Travel and Lodging | $1,275.61 |
| Education | $22.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,363.34 | 2019-2025 | |
| Genentech USA, INC. | $1,826.19 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,345.16 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Gilead Sciences, INC. | $873.67 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $583.28 | 2022-2025 | Dupixent |
| Boston Scientific Corporation | $430.51 | 2019-2021 | |
| Celgene Corporation | $421.85 | 2021-2024 | Zeposia |
| Janssen Biotech, INC. | $354.46 | 2021-2025 | Stelara, Tremfya |
| Pfizer INC. | $335.74 | 2019-2025 | |
| Genzyme Corporation | $307.87 | 2022-2025 | |
| Ironwood Pharmaceuticals, INC | $293.68 | 2022-2025 | Linzess |
| Novo Nordisk INC | $260.78 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Phathom Pharmaceuticals, INC. | $246.28 | 2024-2025 | Voquezna |
| Medtronic, INC. | $219.04 | 2022-2023 | Interstim |
| Daiichi Sankyo INC. | $211.33 | 2022-2023 | Injectafer |
Show all 49 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Herlihy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.